Brooks Laboratories Limited Stock Price Today (NSE: BROOKS)
Fundamental Score
Brooks Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Brooks Laboratories Limited share price today is ₹61.02, down 3.28% on NSE/BSE as of 16 September 2026. Brooks Laboratories Limited (BROOKS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹179.75 (Cr). The 52-week high for BROOKS share price is ₹160.00 and the 52-week low is ₹36.30. At a P/E ratio of 13.59x, BROOKS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 22.24% and a debt-to-equity ratio of 0.06.
Brooks Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Brooks Laboratories Limited share price chart: 5.16% return over the past month. 52-week high ₹160.00, 52-week low ₹36.30.
Brooks Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹64.49 | ₹64.70 | ₹59.13 | ₹61.02 | 51.52K (Cr) | |
| ₹67.70 | ₹67.70 | ₹62.80 | ₹63.09 | 26.35K (Cr) | |
| ₹64.70 | ₹69.72 | ₹63.12 | ₹65.69 | 1.02L (Cr) | |
| ₹66.00 | ₹66.00 | ₹63.10 | ₹63.85 | 24.31K (Cr) | |
| ₹64.61 | ₹65.50 | ₹61.15 | ₹62.99 | 17.28K (Cr) | |
| ₹69.70 | ₹69.75 | ₹61.52 | ₹63.30 | 64.34K (Cr) | |
| ₹66.70 | ₹70.80 | ₹66.60 | ₹67.70 | 25.78K (Cr) | |
| ₹65.95 | ₹66.68 | ₹64.00 | ₹66.07 | 12.92K (Cr) | |
| ₹65.15 | ₹65.95 | ₹64.00 | ₹64.15 | 24.89K (Cr) | |
| ₹66.00 | ₹66.10 | ₹64.00 | ₹65.10 | 23.54K (Cr) |
Brooks Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹67.95 | ₹70.80 | ₹59.13 | ₹61.02 | -10.20% | |
| ₹61.16 | ₹71.40 | ₹58.50 | ₹66.54 | +8.80% | |
| ₹68.86 | ₹79.69 | ₹57.50 | ₹60.98 | -11.44% | |
| ₹68.55 | ₹79.00 | ₹61.61 | ₹68.86 | +0.45% | |
| ₹56.15 | ₹65.29 | ₹44.56 | ₹65.29 | +16.28% | |
| ₹38.98 | ₹79.70 | ₹38.98 | ₹55.98 | +43.61% | |
| ₹63.50 | ₹65.88 | ₹36.30 | ₹37.11 | -41.56% | |
| ₹61.98 | ₹82.44 | ₹58.35 | ₹67.11 | +8.28% | |
| ₹80.50 | ₹80.58 | ₹61.32 | ₹61.55 | -23.54% | |
| ₹103.99 | ₹105.65 | ₹68.11 | ₹80.14 | -22.93% | |
| ₹113.25 | ₹113.69 | ₹95.25 | ₹102.20 | -9.76% | |
| ₹134.25 | ₹138.34 | ₹104.51 | ₹110.93 | -17.37% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Brooks Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Brooks Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BROOKS across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (22.24%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Attractive Valuation (P/E: 13.59 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Profit Growth Track Record (26.75% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.95x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (52.62%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Suboptimal ROCE (5.85%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-13.87%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-118.64%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-10.00%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (2.11% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-78.47 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Brooks Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Brooks Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Brooks Laboratories LimitedBrooks Laborato...Selected✓ BROOKS • 533543 | 58.9/100 | ₹61.02₹61 | ₹179.75₹179.75 | 13.59Average 13.6 Average | 22.24%Excellent 22.24% Excellent | 5.85%Poor 5.85% Poor | 0.06Excellent 0.1 Excellent | 26.75%Excellent 26.75% Excellent | 2.11%Average 2.11% Average | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Brooks Laboratories Limited Quarterly Performance
Latest quarterly metrics for BROOKS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-10.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-118.64%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
2.11%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
26.75%
Compounded annual net profit growth over 5 years
Brooks Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BROOKS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Brooks Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Brooks Laboratories Limited (BROOKS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Brooks Laboratories Limited
About BROOKS (Brooks Laboratories Limited)
Brooks Laboratories Ltd is a dynamic pharmaceutical manufacturer carving a niche for itself in the complex world of drug development and production. They operate as a comprehensive... service provider, collaborating with pharmaceutical companies across India and global markets. Brooks Labs offers a unique blend of innovative solutions and rigorous quality control, functioning as a trusted partner throughout the drug lifecycle. From the initial stages of formulation and analytical development to large-scale commercial manufacturing, the company demonstrates a commitment to precision and efficiency. They aim to empower their partners to bring innovative medications to the market, ensuring accessibility and improved patient outcomes through reliable and cost-effective production processes. The core of Brooks Laboratories' capabilities lies in its diversified manufacturing platform, designed to handle a wide spectrum of pharmaceutical dosage forms. This encompasses advanced sterile injectables, including both liquid and lyophilized formats, crucial for delivering critical medications directly into the bloodstream. Beyond injectables, they also specialize in the production of diverse solid oral dosage forms. These include conventional tablets and specialized dry powder syrups, catered to patient populations of all ages. Furthermore, Brooks Labs maintains dedicated facilities for manufacturing specialized products like ophthalmic and nasal solutions, demonstrating their versatility and commitment to meeting varied therapeutic needs. With this wide-ranging production capacity, Brooks Laboratories positions itself as a versatile manufacturing solution for pharmaceutical innovators. Focusing on critical therapeutic areas, Brooks Laboratories offers robust manufacturing capabilities in high-demand segments like anti-infectives, pain management, and oncology. Their expertise in handling potent and cytotoxic substances allows them to produce complex formulations with precision and safety. These products are often essential treatments for serious illnesses and chronic conditions. Through rigorous adherence to international quality standards and dedicated facilities, Brooks Laboratories ensures the integrity and efficacy of every product they manufacture. This commitment to excellence allows the company to contribute significantly to the global healthcare ecosystem, providing access to life-saving medications and improved quality of life for patients worldwide.
Company Details
Key Leadership
BROOKS Share Price: Frequently Asked Questions
What is the current share price of Brooks Laboratories Limited?
Brooks Laboratories Limited (BROOKS) trades at ₹61.02 on NSE and BSE. Market cap ₹179.75 (Cr). Educational data only.
What is the P/E ratio of Brooks Laboratories Limited?
Brooks Laboratories Limited has a P/E of 13.59x vs industry average 34.89x.
What is the Bull Run score for Brooks Laboratories Limited?
Brooks Laboratories Limited has a Bull Run score of 58.9/100 based on 25+ financial parameters.
Does Brooks Laboratories Limited pay dividends?
Brooks Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Brooks Laboratories Limited?
Brooks Laboratories Limited has ROE of 22.24%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Brooks Laboratories Limited?
Brooks Laboratories Limited has debt-to-equity of 0.06.
Is Brooks Laboratories Limited a good investment?
Bull Run gives Brooks Laboratories Limited a score of 58.9/100. This is not investment advice — consult a SEBI-registered advisor.